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Dynamic contrast enhanced MRI (DCE-MRI) is being used increasingly in clinical trials to demonstrate that vascular disruptive and
antiangiogenic agents target tumour microcirculation. Significant reductions in DCE-MRI kinetic parameters are seen within 4–24 and
48h of treatment with vascular disruptive and antiangiogenic agents, respectively. It is important to know whether cytotoxic agents
also cause significant acute reductions in these parameters, for reliable interpretation of results. This study investigated changes in
transfer constant (K
trans) and the initial area under the gadolinium curve (IAUGC) following the first dose of chemotherapy in patients
with mostly gynaecological tumours. A reproducibility analysis on 20 patients (using two scans performed on consecutive days) was
used to determine the significance of DCE-MRI parameter changes 24h after chemotherapy in 18 patients. In 11 patients who
received platinum alone or with a taxane, there were no significant changes in K
trans or IAUGC in either group or individual patient
analyses. When the remaining seven patients (treated with a variety of agents including platinum and taxanes) were included (n¼18),
there were also no significant changes in K
trans. Therefore, if combination therapy does show changes in DCE-MRI parameters then
the effects can be attributed to antivascular therapy rather than chemotherapy.
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Tumour vasculature is a new promising target for targeted
anticancer therapies; tumour vasculature may be selectively
targeted by ‘vascular disruptive’ agents, which cause rapid blood
vessel shutdown (within minutes with subsequent tumour
necrosis), or the development and subsequent stabilisation of
tumour vasculature may be inhibited by ‘antiangiogenic agents’
(Tozer et al, 2002). Magnetic resonance imaging methods provide
an attractive means of investigating vascular end points (and hence
to evaluate the effectiveness of vascular disruptive and antiangio-
genic agents) as they are widely available, noninvasive and involve
no ionising radiation (Leach et al, 2005).
Dynamic contrast-enhanced (DCE)-MRI is the MRI method
most commonly used. This involves the acquisition of a series
of images over several minutes following the bolus injection of
a contrast agent. Low molecular weight (o1kDa) gadolinium
chelates are usually used as contrast agents. These are small
enough to diffuse out of blood vessels into tissue extravascular,
extracellular spaces (EES), inducing an increase in signal intensity
on T1-weighted MR images (Padhani and Dzik-Jurasz, 2004). The
curve of signal intensity change following contrast agent injection
indicates the rate of uptake of contrast agent into a tissue and its
subsequent washout (Leach et al, 2005). Quantitative parameters
relating to tissue blood flow rate, permeability surface-area
product and EES volume (all of which influence the rate and
magnitude of enhancement seen) are obtained from modelling of
contrast agent kinetics (Tofts and Kermode, 1991; Tofts, 1997).
DCE-MRI has been used to evaluate vascular disruptive and
antiangiogenic agents in both xenograft studies and human trials.
Significant reductions in tumour DCE-MRI kinetic parameters are
seen within 4–24h with vascular disruptive agents (Dowlati et al,
2002; Evelhoch et al, 2002; Galbraith et al, 2002b, 2003; Maxwell
et al, 2002; Stevenson et al, 2003) and by 48h with antiangiogenic
agents (Gossmann et al, 2002; Jayson et al, 2002; Checkley et al,
2003a,b; Morgan et al, 2003).
As DCE-MRI is used in early clinical trials to confirm that
vascular disruptive and antiangiogenic agents target vasculature,
it is important to know whether cytotoxic agents also have
acute effects on vasculature. As well as aiding in the classification
of agents according to their method of action, such information
would also help in planning combination therapy and interpreting
DCE-MRI results of such combination therapy.
The acute effects of cytotoxic agents on DCE-MRI kinetic
parameters have not previously been reported, although measure-
ments have been performed after 1–2 cycles of treatment
(Barentsz et al, 1998; Reddick et al, 1999; Wolf et al, 2003;
Ah-See et al, 2004). However, at these time-points objective tumour
shrinkage and pathological response may also be seen, so changes
in DCE-MRI parameters may be due to a reduction in blood flow
secondary to tumour cell kill rather than due to direct antivascular
effects. Animal studies suggest that apart from possibly the vinca
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salkaloids, significant acute vascular disruptive effects are unlikely
(Chaplin and Hill, 2002), but longer term antiangiogenic effects of
chemotherapy are recognised (Miller et al, 2001).
This study investigates the acute DCE-MRI effects of conven-
tional cytotoxic agents measured 24h after the start of the first
cycle of treatment. Most patients had gynaecological cancers with
pelvic or abdominal masses. All chemotherapy regimens included
a taxane and/or platinum agent, as these are being used in
combination therapy in current/future clinical trials. Taxanes exert
their cytotoxic effects by inhibiting spindle formation but act by
stabilising microtubules rather than inducing depolymerisation, so
do not have acute vascular disruptive properties (Jordan et al,
1998; Wang et al, 2000). Platinums are alkylating agents that
bind to DNA, inducing crosslink formation (Cavalli et al, 2000).
Belotti et al (1996) found that both cisplatin and paclitaxel have
antiangiogenic effects in vitro, but only paclitaxel had antiangio-
genic effects in vivo.
MATERIALS AND METHODS
Local ethics committee approval for the trial protocol and written
informed consent from all participating patients was obtained.
Eligibility criteria for the study were: histologically confirmed
cancer at an anatomical site suitable for imaging with MRI; tumour
mass X3cm in diameter; patient due to start first cycle of taxane
or platinum-based chemotherapy regimen; calculated creatinine
clearance 450mlmin
 1; WHO performance status p2; age X18
years; no history of allergic reaction to contrast agents.
Three DCE-MRI scans were performed on consecutive days: two
prechemotherapy to assess the reproducibility of the technique
and one 20–24h after the start of the first cycle of chemotherapy
to assess response. Duration of taxane or platinum infusion varied
from 1h (carboplatin, docetaxel) to 6h (cisplatin). Details of
chemotherapy regimens used are given in Table 1.
The MRI studies were performed on a 1.5T, Magnetom
Symphony scanner (Siemens Medical Systems, Erlangen,
Germany), using a body phased array coil. In the first scanning
session, initial T1 and T2-weighted anatomical images were
obtained to select four suitable contiguous slices through the
centre of a tumour mass. Care was taken to place the scans in
the same position on the follow-up sessions in order to obtain the
same anatomical slice location. This was carried out by reference
to bony landmarks, by employing the same technologist for each
patient visit and by confirming acceptable anatomical relocation
by the study radiologist in the quality control process prior to
analysis. Proton density-weighted spoiled gradient-recalled echo
(GRE) images were acquired first (echo time TE 4.7ms, repetition
time TR 350ms, flip angle 61, slice thickness 8mm, four slices).
Then an interleaved dynamic series of 40 T1-weighted GRE images
were acquired (TE 4.7ms, TR 11ms, flip angle 351, slice thickness
8mm, four slices, and total imaging time 8min 5s) at the same
slice positions. The contrast agent, gadopentetate dimeglumine
(Gd-DTPA, Magnevist
s, Schering Health Care Ltd, Burgess Hill,
UK), was injected intravenously using a power injector (dose
0.1mmolkg
 1 bodyweight) at 4mls
 1 during the fifth acquisition.
System gain and scaling factors were maintained between
acquisition of the proton density and T1-weighted dynamic series
of images to enable the calculation of tissue contrast agent
concentration (Parker et al, 1997).
Images were transferred to a Sun Ultra 60 workstation (Sun
Microsystems, Mountain View, CA, USA) and analysed using
specialist software (Magnetic Resonance Imaging Workbench
(MRIW), Institute of Cancer Research, London UK) (Parker
et al, 1998). Using information from anatomical and postcontrast
T1 images, regions of interest (ROIs) were carefully drawn around
the tumour edges for each examination by a single operator who
carefully excluded areas of artefacts and blood vessels. The intra-
observer variability for ROI drawing for this operator has been
documented to be less than 5% (Beresford et al, 2005).
Quantitative analysis required conversion of the MRI signal
intensities to T1 relaxation rates and then to Gd-DTPA concentra-
tions following the methods described by Parker et al (1997).
These processes are carried out in the MRIW software.
Gd-DTPA concentration at time t, Ct(t), was calculated from the
tissue T1 using the equation
CtðtÞ¼
ð1=T1ðtÞ 1=T1ð0ÞÞ
r1
where T1(0) is the tissue T1 without contrast and r1 is the
longitudinal relaxivity of protons in vivo due to Gd-DTPA (taken
to be 4.5mM
 1s
 1 at 1.5T) (Donahue et al, 1994).
MRIW software calculates several kinetic parameters. The initial
area under the Gd-DTPA concentration time curve (IAUGC – in
mMs) was calculated for the first 60s following arrival of contrast
agent in the tumour. Then, the data were fitted to a standard
compartmental model (Kety, 1960), to characterise the arterial
influx of Gd-DTPA into the tumour EES and its venous efflux.
Using this model, the time course of contrast agent concentration
in tissue can be described by
CtðtÞ¼Ktrans½CpðtÞ expð keptÞ 
where Cp(t) is the Gd-DTPA concentration in arterial blood plasma
at time t; K
trans is the transfer constant for transport from plasma
to the tumour EES (min
 1), kep is the rate constant for transport
from the EES back to plasma (min
 1) and # denotes the
convolution integral. An assumed arterial input function (AIF) was
used for the modelling procedure (Weinmann et al, 1984; Tofts,
1997) as described previously (Galbraith et al, 2002a).
Values were calculated on a voxel-by-voxel basis for K
trans.
Voxels that did not enhance and those enhancing voxels that failed
the modelling process or had values 45.0min
 1 were excluded
from analysis. The analysis was performed on combined voxel data
from all slices containing tumour, taking the median voxel value
as representative of central tendency. Median rather than the
mean voxel values were used as the histogram distributions of
some kinetic parameters were skewed.
Data were statistically analysed using StatsDirect software (Sale,
UK). The statistical analysis used to determine reproducibility has
been described previously (Bland and Altman, 1996a,b; Galbraith
et al, 2002a; Padhani et al, 2002). The key statistical parameters
are the 95% confidence intervals for change for a group of n
patients and for an individual patient (the latter also known as the
repeatability statistic). The 95% confidence intervals can then be
used to determine whether a change in a kinetic parameter
following an intervention is statistically significant or not (see
below). The within-patient coefficient of variation (wCV) was also
calculated. In addition, the intra-class correlation coefficient (ICC),
which gives an estimate of the reliability of the measurement
method, and the ratio of between-patient variance to the within-
patient variance, F (obtained from a one-way analysis of variance –
ANOVA), were obtained.
In summary, for each patient, the difference d between the two
pretreatment measurements of a parameter was calculated. Data
were transformed using natural logarithms if the variability of d
was found to depend on its mean value (Bland and Altman, 1996b).
The square root of the mean squared difference, dsd, (¼O[(Sd
2)/
n] where n is the number of patients) was then calculated. The 95%
confidence interval for change for a group of n patients is then
equal to 7(1.96 dsd)/On). For an individual patient, n¼1 so the
95% confidence interval for change is equal to 7(1.96 dsd),
which is also known as the repeatability statistic, r (Bland and
Altman, 1996a).
The within-patient standard deviation wSD¼dsd/O2, as there
are two pretreatment measurements. This is a measure of the
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sTable 1 Patient details
Patient
number
Age
(years) Tumour type
Tumour size
(cm
2)
#
Tumour site
imaged Chemotherapy regimen
a
No. of prior
chemotherapy
regimens Outcome
1 55 Adeno-carcinoma, ovary 25.5 Pelvis – LR Carboplatin AUC 6
b 1 Stable disease
c
2 59 Adeno-carcinoma, ovary 41.3 Pelvis – P Carboplatin AUC 6 0 Stable diseases
c
3 46 Adeno-carcinoma, ovary 65.4 Anterior abdominal
wall – M
Carboplatin AUC 5, Paclitaxel 175mgm
 2 0 Stable disease
c
4 66 Adeno-carcinoma, ovary 25.7 Para-aortic lymph
nodes – M
Carboplatin AUC 5 0 Progressive disease
d
5 73 Clear cell carcinoma, ovary 69.5 Pelvis – LR Carboplatin AUC 6 2 Stable disease
c
6 42 Primary peritoneal carcinoma 39 Pelvis – LR Cisplatin 25mgm
 2, Docetaxel
60mgm
 2weekly
5 Stable disease
c
7 62 Adeno-carcinoma, ovary 112.1 Pelvis – LR Cisplatin 60mgm
 2, Docetaxel 40mgm
 2
weekly
1 Partial response
c
8 45 Adeno-carcinoma, ovary 86.7 Pelvis – P Carboplatin AUC 6 0 Stable disease
d
9 54 Adeno-carcinoma, ovary 6.8 Pelvis – LR Carboplatin AUC 6 2 Partial response
c
10 46 Adeno-carcinoma, ovary 7.4 Pelvis LR Carboplatin AUC 6 1 Stable disease
c
11 67 Primary peritoneal carcinoma 103.4 Pelvis – LR Carboplatin AUC 6, Paclitaxel 175mgm
 2 1 Partial response
d
12 70 Mixed mullerian tumour/
carcinosarcoma
153.6 Pelvis – P Cisplatin 60mgm
 2, Doxorubicin 60mgm
 2 0 Not evaluable – only 1
cycle given
13 65 Mixed mullerian tumour 93.8 Pelvis – P Cisplatin 70mgm
 2, Epirubicin 70mgm
 2 0 Partial response
d
14 57 Adeno-carcinoma, ovary 66.2 Pelvis – LR Docetaxel 80mgm
 2 day 1, Gemcitabine
1250mgm
 2 days 1 & 8
2 Partial response
c
15 49 Granulosa cell tumour, ovary 45.5 Pelvis – P Bleomycin 30mg days 2, 8, 15, Etoposide
165mgm
 2days 1–3, Cisplatin 50mgm
 2
days 1 & 2.
0 Partial response
d
16 59 Primitive neuro-ectodermal
tumour
50.4 Pelvis – P Cisplatin 50mgm
 2 days 1&2, Etoposide
150mgm
 2 days 1, 2, 3
0 Partial response
d
17 66 Adenocarcinoma ovary 139.9 Pelvis – LR Cisplatin 60mgm
 2 weekly, Etoposide 50mg
p.o. for every 21/28 days
4 Not evaluable – only 1
cycle given
18 52 Adenocarcinoma,
endometrium
53.7 Pelvis – P Cisplatin 60mgm
 2, Doxorubicin 60mgm
 2 0 Partial response
d
19 74 Poorly differentiated
carcinoma? Ovary? Primary
peritoneal carcinoma
34.5 Anterior abdominal
wall – M
Carboplatin AUC 5 0 Not evaluable – only 1
cycle given
20 29 Squamous cell carcinoma,
cervix
4.5 Cervix – P Cisplatin 60mgm
 2, Bleomycin 30mgm
 2,
Methotrexate 300mgm
 2
0 Not evaluable – had
surgery after 1 cycle
P.O.: orally; AUC: area under the curve; bd: twice daily.
aChemotherapy given intravenously and repeated every 3 weeks unless otherwise stated. LR: local recurrence; P: primary; M: metastatic disease.
bCarboplatin dose calculated
according to AUC (area under the plasma concentration–time curve).
cCA-125 criteria. Patients 1–11 received platinum or taxane agents only. Patients 19 and 20 had complete data sets for days 1 and 2 only.
dRECIST.
#Tumour size
measured on central slice.
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Clinical Studiesprecision of the measurement error. The difference between a
patient’s parameter measurement and the true value is expected to
be less than 1.96 wSD for 95% of observations. The wCV is then
obtained by dividing wSD by the group mean pretreatment value
for each parameter. wCV quantifies measurement error relative
to the size of the (positive) kinetic parameters. If data had to be
transformed, then wCV was approximated by wCV¼e
wSD 1
(Bland and Altman, 1996b).
The results of the reproducibility analysis were then used to
assess whether there had been a statistically significant change in
kinetic parameters due to chemotherapy, either for individual
patients or the group. As there were two pretreatment measure-
ments (days 1 and 2), the mean of the two pretreatment
examinations was taken as the pretreatment value for each
parameter. The null hypothesis was that there would be no
difference between this combined pretreatment value and the post-
treatment value, that is, there would be no changes seen at 24h
following treatment.
For individual patients, the repeatability statistic, r, expressed as
a percentage of the group mean pretreatment value for each
parameter, gives a range within which the difference between
pre- and post-treatment values would be expected to lie for 95%
of observations, assuming that the null hypothesis is true. If the
difference falls outside this range for a particular kinetic
parameter, then a significant change was deemed to have occurred.
Similarly, to assess mean response in the group, the 95%
confidence interval for change, expressed as a percentage of the
group mean pretreatment value, gives the range required.
RESULTS
In total, 24 female patients were imaged. The average age was 56
years old (range, 29–74 years). Data from four patients were
excluded from analysis (three technical failures, one voluntary
patient motion). Data from the remaining 20 patients were used
for the reproducibility analysis (the two pretreatment scans). Post-
treatment (day 3) data were available for 18 patients (data could
not be obtained from all slices on day 3 for one patient due to
internal organ motion and one patient was unable to complete
the post-treatment scan, due to treatment toxicity). In total,
11 patients received a taxane or platinum agent only (numbers
1–11, Table 1). The remaining patients received a taxane and/or
platinum based regimen, with the addition of other agents. The
average time from the start of chemotherapy to the third scan was
21h (range 17–23h). Whole-group analysis regardless of the
chemotherapy used was performed; those patients who received
taxane or platinum chemotherapy (n¼11) were also analysed
separately for antivascular effects.
Table 1 shows patient details including diagnosis, tumour area
(taken from central slice), chemotherapy regimen used and
response to treatment. Most tumours had both solid and cystic
components. Patient order corresponds to that given in the figures
(see below). Overall response was assessed after three cycles of
chemotherapy either on CT or MRI imaging or by CA125
measurements (based on RECIST or CA125 criteria) (Therasse
et al, 2000; Rustin, 2003).
Table 2 summarises the results of the reproducibility analysis for
tumours. The individual patient repeatability for tumour K
trans and
IAUGC were  40.0 to þ66.7%, and 733.7%, respectively. For the
whole group with day 3 data (n¼18), the 95% confidence intervals
for change (expressed as percentage of the group mean pretreat-
ment value) were –11.9 to þ13.6% and 78.8% for tumour K
trans
and IAUGC, respectively. For the subgroup receiving platinum/
taxane agents only, the 95% confidence intervals for change were
 15.3 to þ18.1% and 712.0% for tumour K
trans and IAUGC,
respectively (NB K
trans confidence intervals are asymmetrical due
to the log transformation because the difference between the two
pretreatment measures was found to depend on the mean value
(Bland and Altman, 1996b)).
Figure 1A and B show tumour pretreatment values (mean of the
two pretreatment examinations), the post-treatment values and
Table 2 Results of the reproducibility analysis
Statistical variable K
trans IAUGC
Mean 0.39 6.36
dsd 0.26 1.09
wCV (%) 20.30% 12.10%
r 0.51 2.14
r (%) for individual patient  40.0 to +66.7% 733.7%
r (%) for group (n¼11)  15.3 to +18.1% 712.0%
r (%) for group (n¼18)  11.9 to +13.6% 78.8%
ICC 0.76 0.92
F 7.84 25.4
K
trans: transfer constant; IAUGC: initial area under the gadolinium concentration time
curve; mean: group mean pretreatment value; dsd: squared root of the mean squared
difference; wCV: within-patient coefficient of variation; r: individual patient
repeatability; r( % )individual patient: repeatability as a percentage of the mean for
an individual patient; r (%) group: repeatability for the group of patients (n¼11 or
18). ICC: interclass correlation coefficient; F: ratio of between-patient variance to
within-patient variance.
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Figure 1 Results for individual patients. (A and B)( K
trans and IAUGC)
Mean pretreatment (grey circle) and post-treatment values (black square)
and the repeatability range for each parameter. Patients are ordered by
mean pretreatment K
trans value, demonstrating that the repeatability range
is dependent on mean pretreatment value. Patient numbered 1–11
received a platinum or taxane only. The rest received a platinum or taxane
plus other chemotherapy agents (see Table 1).
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srepeatability ranges for K
trans and IAUGC, respectively, for each
patient (patient order corresponds to Table 1). There were no
significant changes post-treatment in K
trans (Figure 1A) or in
IAUGC (Figure 1B).
When data were analysed as a group (n¼11) for the patients
who received a platinum or taxane only, again there were no
significant changes in K
trans or IAUGC. When all patients were
included in the analysis (n¼18), there were no significant changes
in individual K
trans. Two patients had significant increases
(numbers 12 and 14 in Table 1: increases of 57.0 and 43.5%,
respectively) in IAUGC and one patient had a significant decrease
(no. 15: decrease of 39.3%). There were no significant changes in
group K
trans or IAUGC.
DISCUSSION
In this study we were very careful with patient selection to only
include those who had lesions in body parts that showed little
respiratory motion; this accounts for the low failure rate for our
DCE-MRI examinations. This was carried out because we wanted
to optimise the DCE-MRI technique and to obtain a large group of
patients that received platinum and taxane-based chemotherapy.
As a result, most of our patients had tumours of pelvic origin. Our
patient population was therefore not typical of phase 1 clinical
studies, which would ordinarily have a more heterogeneous group
of patients including metastatic lung and liver lesions.
The reproducibility analysis shows that there is a wide inherent
variability in individual patient repeatability for K
trans and IAUGC.
This level of reproducibility has also been found in previous
studies. In a phase I study of the vascular disruptive agent,
Combretastatin A-4-phosphate (CA-4-P), the individual repeat-
ability for K
trans was  44 to þ79% and the 95% confidence
intervals for change in 16 patients was  14 to þ16%) (Galbraith
et al, 2003). Evelhoch et al also performed a reproducibility
analysis as part of a phase I study of ZD6126, another vascular
disruptive agent. The wCV was 718% for tumour IAUGC (n¼16,
scans performed 2–6 days apart, with no treatment in the
intervening period) (Evelhoch et al, 2004). From the data given
in Evelhoch’s et al (2004) paper, the individual patient repeat-
ability can be calculated as 748.9% and the group 95% confidence
interval for change as 711.2% for IAUGC. However, in both these
trials, significant reductions in DCE-MRI kinetic parameters were
still seen. The CA-4-P study was performed at our centre and the
same methods used for T1 calculation and to obtain K
trans. In the
CA-4-P study, there was a group mean reduction in K
trans of 29%
for 16 patients 24h following treatment with X52mgm
 2 CA-4-P.
When analysed as individuals, there were reductions in K
trans in
three patients greater than the limits set by the repeatability
statistic (Galbraith et al, 2003). In the ZD6126 study, there was
a significant group mean reduction in tumour IAUGC of 38.7%
(nine patients, 10 tumours, measured 6h after administration of
56–112mgm
 2 ZD6126) and three of these patients had reduc-
tions in IAUGC greater than the limits set by the repeatability
statistic (Evelhoch et al, 2004). In comparison, in our study there
was no significant reduction in group K
trans or IAUGC. Given the
wide within-patient variation in K
trans and IAUGC, it is not
possible to state that the cytotoxic agents tested have no acute
effects on tumour vascularity. However, based on the results from
this study, one is unlikely to expect large antivascular effects in the
acute setting due to cytotoxic agents alone. Therefore, if significant
acute reductions in K
trans and IAUGC seen in combination
cytotoxic and antivascular therapies, one may presume they are
due to the vascular disruptive agent (or a synergistic effect with the
cytotoxic agent).
Chaplin and Hill (2002) compared the acute effects of CA-4-P
with a number of cytotoxic agents, including cisplatin and
paclitaxel, in the murine CaNT tumour. Change in functional
vascular volume (measured using Hoechst 33342) at 24h after drug
administration was used to assess vascular disruptive activity.
There was a 480% reduction in functional vascular volume
following treatment with CA-4-P, but no reduction following
treatment with any of the cytotoxic agents (Chaplin and Hill,
2002). CA-4-P is classified as a tubulin depolymerising agent
(Thorpe, 2004). The vinca alkaloids are also tubulin depolymeris-
ing agents, exerting their cytotoxic effects by the inhibition of
spindle formation and subsequent mitotic arrest (Jordan et al,
1998). However, whereas CA-4-P induces acute blood vessel
shutdown at 1/10th of the maximum tolerated dose (MTD) in an
animal model (Dark et al, 1997), the vinca alkaloids only have
sustained vascular disruptive effects at close to the MTD (Baguley
et al, 1991; Hill et al, 1993, 1995; Chaplin et al, 1996; Sersa et al,
2001). Several cytotoxic agents do have a degree of antiangiogenic
activity (based on in vitro and in vivo assays) (Miller et al, 2001)
and continuous low-dose scheduling of cytotoxic agents can
produce antiangiogenic effects (Browder et al, 2000; Colleoni et al,
2002; Kerbel et al, 2002). However, as there are no set criteria
for defining antiangiogenic activity, it is difficult to establish its
relative importance in comparison with an agent’s cytotoxic action
(Miller et al, 2001).
DCE-MRI, using low molecular weight contrast agents such as
Gd-DTPA, is now widely available and can be incorporated into
clinical trials relatively easily. K
trans has both blood flow rate
and permeability components (as Gd-DTPA is not freely diffusible)
and its biological meaning is dependent on the balance
between capillary permeability and blood flow in the tissue of
interest (Tofts, 1997; Tofts et al, 1999). For extra-cranial tumours,
the blood flow component dominates K
trans (Tofts, 1997; Tofts
et al, 1999) and the usage of K
trans to monitor the vascular effects
of drugs is now accepted. This has been validated by Maxwell et al
(2002), who showed that changes in K
trans (and IAUGC) in
response to CA-4-P in a rat carcinosarcoma model matched
changes in blood flow rate measured using uptake of
125I-
iodoantipyrine (IAP). Moreover, the pattern and time course of
changes in K
trans seen in a clinical phase I trial of CA-4-P was
similar to that seen in animal models (Galbraith et al, 2003),
indicating the appropriateness of using K
trans as a surrogate
marker of vascular response to treatment. This view has been
endorsed by specialist panels, meeting under the auspices of Cancer
Research UK (CR-UK) (Leach et al, 2005) and the US National
Cancer Institute (http://imaging.cancer.gov/reportsandpublications/
ReportsandPresentations/MagneticResonance).
Two patients had small but significant increases in IAUGC. One
(patient 14) went on to have a partial response to chemotherapy
and the other (patient 12) was not evaluable for response (see
Table 1). The IAUGC parameter cannot be simply related to
tumour physiology, but it is a quantitative parameter that may
be obtained without mathematical modelling. In our study,
IAUGC correlated very strongly with K
trans (Spearman’s r: 0.86,
Po0.0001), confirming that it is an appropriate biomarker for
antivascular effect. These increases do not fit into a pattern
consistent with an antivascular effect (see above) and the cause
for this effect is also uncertain, but could be related to increased
blood flow. Griffon-Etienne et al (1999) reported on the use of
intravital microscopy to measure red cell flux (the number of red
cells passing a point per minute) and found an increase in the first
few days following administration of paclitaxel or docetaxel. An
increase in relative tumour blood flow rate has also been seen
following cyclophosphamide and 5-fluorouracil (measured using
86Rubidium chloride extraction) (Braunschweiger, 1988; Li et al,
1991). These changes may be due to reduced blood vessel
compression secondary to tumour cell kill resulting in reductions
in interstitial fluid pressure (Griffon-Etienne et al, 1999).
There are uncertainties with regard to the reliability of kinetic
parameter estimates derived from the application of tracer kinetic
models to T1-weighted DCE-MRI data. These derive from
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measurement of tissue contrast agent concentration. For example,
the Tofts’ model uses a standard description of the time varying
blood concentration of contrast agent (the arterial input function),
and assumes that the supply of contrast medium is not flow limited
and that tissue blood volume contributes negligibly to signal
intensity changes compared with that arising from contrast
medium in the interstitial space. We have used a two-point
technique (proton density and initial T1-weighted image) to
calculate relaxation values. There are alternative schemes for
calculating these values that may be more accurate. However, it
should be noted that there are no head to head comparisons of
such techniques. The technique that we have used has been used
successfully to assess vascular response to therapy. Furthermore,
international consensus meetings have recognised that this is
a controversial area and have sort not to be prescriptive in
this regard (Leach et al, 2005) and (http://imaging.cancer.gov/
reportsandpublications/ReportsandPresentations/MagneticResonance).
It is necessary to briefly address the issue of voxels that fail the
modelling process, which occurs when the Tofts’ model does not
fit the Gd-DTPA concentration–time curve. This occurs princi-
pally because voxels are sited over blood vessels (100% blood
volume) or are in tissues with a large blood volume. In such
situations, semiquantitative parameters such as IAUGC can still be
used to assess tissue enhancement and tissue response to therapy.
However, as noted above, the IAUGC parameter cannot be simply
related to tumour physiology; in this study, IAUGC was shown to
correlated very strongly with K
trans (see above). Interested readers
are invited to review the recent article by Collins and Padhani
(2004), where these issues are comprehensively discussed. Despite
these complexities, it is important to remind readers that
quantitative kinetic parameters can provide insights into under-
lying tissue patho-physiological processes and it is possible to use
quantitative DCE-MRI as a tool for decision making in the clinic
and pharmaceutical drug development.
In summary, within 24h after taxane/platinum-based chemo-
therapy regimens, no significant reductions in kinetic parameters
derived from T1-weighted dynamic MRI are seen. However, it is
not possible to state categorically that cytotoxic agents tested have
no acute effects on tumour vascularity (if they are present, then
they are beyond the resolution of our technique). Nevertheless,
based on the results from this study, it is unlikely to expect large
antivascular effects in the acute setting due to cytotoxic agents
alone. Therefore, if significant acute reductions in K
trans and
IAUGC seen in combination cytotoxic and antivascular therapies,
one may presume they are due to the vascular disruptive agent.
This is the first demonstration that cytotoxic agents differ from
vascular disruptive agents in their effect on DCE-MRI parameters
in humans, thus validates the use of DCE-MRI as a biomarker of
targeting activity.
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